BTIG raised the firm’s price target on RxSight to a “Street-high” $61 from $43 and keeps a Buy rating on the shares. The firm is citing the company’s positive Q4 pre-announcement and expectations that the high short interest on the stock will come down as shorts look for more near-term opportunities since “everything is largely already known at this point,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXST:
- RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- RxSight price target raised to $54 from $45 at Stifel
- RxSight price target raised to $41 from $35 at Needham
- RxSight up 9% in pre-market after above-consensus pre-announcement for Q4
- RxSight price target raised to $45 from $40 at Stifel
